23948sdkhjf

Fakta om udbudet

EU-nr
2018/S 203-462315
Offentliggjort
20.10.2018
Udbudstype
Tildeling af kontrakt uden forudgående offentliggørelse

Udbyder

Kungliga Tekniska högskolan

Vindere

(20.10.2018)
Icosagen Cell Factory OÜ
Õssu

Direct Procurement of ReAgent 007, a Transient Transfection Reagent for a High-throughput Midscale Protein Production in Chinese Hamster Ovary (CHO) Cells


Kungliga Tekniska högskolan

Voluntary ex ante transparency notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1) Name and addresses
Kungliga Tekniska högskolan
202100-3054
Teknikringen 30
Stockholm
10691
Sweden
Contact person: Kicki Holmberg
E-mail: hoki@kth.se
NUTS code: SE11

Internet address(es):

Main address: http://www.kth.se

I.4) Type of the contracting authority
National or federal agency/office
I.5) Main activity
Education

Section II: Object

II.1) Scope of the procurement
II.1.1) Title:

Direct Procurement of ReAgent 007, a Transient Transfection Reagent for a High-throughput Midscale Protein Production in Chinese Hamster Ovary (CHO) Cells

Reference number: C-2018-1648
II.1.2) Main CPV code
33696500
II.1.3) Type of contract
Supplies
II.1.4) Short description:

The Human Secretome project within the Wallenberg Center for Protein Research (WCPR) at the Royal Institute of Technology (KTH) has set up a high-throughput protein production pipeline to be able to produce a large number of recombinant proteins in CHO cells yearly. Now the production will change from small scale to midscale to produce higher amounts of each protein. To be able to achieve this a chemical transient transfection reagent is needed and for that the reagent “ReAgent 007” is to be purchased.

II.1.6) Information about lots
This contract is divided into lots: no
II.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: 304 000.00 EUR
II.2) Description
II.2.1) Title:
II.2.2) Additional CPV code(s)
II.2.3) Place of performance
NUTS code: SE110
II.2.4) Description of the procurement:

It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins. We have established a robust production pipeline with this technology and we will now shift the production from small scale to midscale using the same cells and vectors. During the last year we have evaluated different protocols, testing culture media, feed media, shake flasks and transfection reagents for the upscaled production. The chosen protocol, for maximum transfection efficiency in the Icosagen system includes a transfection reagent that is produced and distributed by Icosagen Cell Factory. ReAgent007, the transfection reagent chosen, was the only one fulfilling our demands. For example, resulting in the highest transfection efficiency leading to high enough protein amounts in a minimum culture volume and thereby the upscaled production can be performed in our already existing laboratory equipment.

II.2.5) Award criteria
II.2.11) Information about options
Options: no
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14) Additional information

Section IV: Procedure

IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
  • The procurement falls outside the scope of application of the directive
Explanation:

The Human Secretome project within the WCPR at KTH has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319) developed by the Estonian company Icosagen Cell Factory OÜ. It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins and has been chosen after extensive testing of different expression systems. Today we have generated over 3,000 expression vectors that all are designed to work exclusively in Icosagen QMCF cells. Next step for our production is to produce higher amounts of each protein using these cells and vectors and still keeping a high-throughput pipeline. During the last year one of the researchers in the ProteinFactory group has evaluated different protocols. For example, different culture media, feed media, shake flasks and transfection reagents have been evaluated for the upscaled production. The optimized protocol now chosen for maintaining a high-transfected cell density, viability, and to achieve the highest titers in the Icosagen system includes a transfection reagent that is produced and distributed by Icosagen Cell factory. This new cultivation protocol also works in a high-throughput way that is necessary for our production pipeline.

Because of the above stated reasons it is crucial for our upscaled production that we are able to buy this transfection reagent from the Icosagen Cell Factory Company that is the manufacturer of this transfection reagent and the only company that sells this product.

IV.1.3) Information about framework agreement
IV.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure

Section V: Award of contract/concession

V.2) Award of contract/concession
V.2.1) Date of contract award decision:
16/10/2018
V.2.2) Information about tenders
The contract has been awarded to a group of economic operators: no
V.2.3) Name and address of the contractor/concessionaire
Icosagen Cell Factory OÜ
11107818
Õssu
Estonia
NUTS code: EE
The contractor/concessionaire will be an SME: yes
V.2.4) Information on value of the contract/lot/concession (excluding VAT)
Initial estimated total value of the contract/lot/concession: 304 000.00 EUR
Total value of the contract/lot/concession: 304 000.00 EUR
V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information:
VI.4) Procedures for review
VI.4.1) Review body
Förvaltningsrätten i Stockholm
Stockholm
Sweden
VI.4.2) Body responsible for mediation procedures
VI.4.3) Review procedure
VI.4.4) Service from which information about the review procedure may be obtained
VI.5) Date of dispatch of this notice:
17/10/2018

Send til en kollega

0.11